* enVVeno Medical Corp NVNO.OQ NVNO.O is expected
to show no
change in quarterly revenue when it reports results on October
23 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for enVVeno Medical Corp is
for a
loss of 33 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for enVVeno
Medical
Corp is $18.00, above its last closing price of $3.33.
This summary was machine generated October 21 at 22:03 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)